Talecris Biotherapeutics Holdings Corp

May 26, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

Talecris Biotherapeutics Holdings Corp Company Summary

Talecris Biotherapeutics Holdings Corp. is a biopharmaceutical company that is a producer and marketer of plasma-derived protein therapies in the world. The Company develops, produces, markets and distributes therapies that help people suffering from conditions, such as immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns. The Company’s largest product, Gamunex Immune Globulin Intravenous (Human), is one of the products in the intravenous immune globulin (IGIV) market. Its second largest product, Prolastin Alpha 1 Proteinase Inhibitor (Human), was granted orphan drug status and has a 71% share of sales in the United States, a 78% share of sales in the European Union and brand recognition within the alpha-1 proteinase inhibitor (A1PI) category. In June 2007, it acquired three additional plasma collection centers from International BioResources, L.L.C. (IBR).

COMPANY DATA

	Principal Sector	Biotech IT

	Principal Industry	Biotechnology

	Homepage	www.talecris.com

Key Developments: Talecris Biotherapeutics Holdings Corp

	Australia Market Report of August 13: Slowdown Faster Than Expected AUG 13, 2008 12:30 - Article Views: 5,086 The Australian share market closed higher on Tuesday. The benchmark S&P/ASX200 index rose 27.5 points to 5053.6, while the broader All Ordinaries rose 21 points to 5090.3.